FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)

On Wednesday, the U.S.

Food and Drug Administration (FDA) granted early approval to GSK plc's (NYSE:GSK) targeted lung cancer medication, Jideytro (zidesamtinib).

The regulatory green light authorizes the therapy for adult patients facing locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously undergone treatment with a ROS1 kinase inhibitor.

Significantly, the agency issued its approval ahead of the original target action date set for September 18.

Read Also: Disappointing Data Prompts GSK to Drop Cough Drug Development Overcoming Resistance And Targeting Brain Metastases Jideytro became part of the pharmaceutical giant's pipeline following the recently completed acquisition of Nuvalent.